CN105288049A - Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases due to static blood obstructing the collaterals - Google Patents
Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases due to static blood obstructing the collaterals Download PDFInfo
- Publication number
- CN105288049A CN105288049A CN201510833658.5A CN201510833658A CN105288049A CN 105288049 A CN105288049 A CN 105288049A CN 201510833658 A CN201510833658 A CN 201510833658A CN 105288049 A CN105288049 A CN 105288049A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- collaterals
- ethanol
- eluting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases due to static blood obstructing the collaterals, discloses a preparation method, and belongs to the technical field of a Chinese herbal medicine. The traditional Chinese medicine composition comprises rhizoma dioscoreae nipponicae, ligusticum wallichii, musk, and borneol, and can be prepared into dosage forms of tablet, granula, capsule, drop pill, and soft capsule. The traditional Chinese medicine composition is significant in therapeutic effect, and has no toxic or side effect. The therapeutic traditional Chinese medicine composition has the efficacy of activating blood and resolving stasis, and relieving the stuffy nose to relieve pain, and is an ideal medicine for treating cardiovascular and cerebrovascular diseases due to static blood obstructing the collaterals.
Description
Technical field
The present invention relates to field of Chinese herbal medicine technology, be specifically related to a kind ofly treat cardiovascular and cerebrovascular diseases caused Chinese medicine composition of obstruction of collaterals by blood stasis and preparation method thereof.
Background technology
Cardiovascular and cerebrovascular disease are referred to as cardiovascular and cerebrovascular disease, make a general reference because ischemic or hemorrhage occur for the heart that hyperlipemia, blood are sticky, atherosclerosis, hypertension etc. cause, brain and body tissue.Its cardiovascular disease comprises the diseases such as hypertension, angina pectoris, myocardial infarction; Cerebrovascular disease comprises the diseases such as cerebral thrombosis, cerebral embolism and cerebral apoplexy sequela.In old people, sickness rate is higher, at present along with the raising of quality of life, in the young and the middle aged, sickness rate also improves year by year, and the number of cardiovascular and cerebrovascular disease is died from every year up to 15,000,000 people in the whole world, China dies from nearly 3,000,000 people of cardiovascular and cerebrovascular disease every year, accounts for 51% of the annual total Death causes of China.
Cardiovascular and cerebrovascular disease is a kind of commonly encountered diseases, main cause is exactly that the reasons such as own physiological factor or diet be unreasonable cause the improper metabolism of vascular smooth muscle cell to cause, thorough healing is also not easy, China's patient with cerebral apoplexy leave hospital after the relapse rate of First Year be 30%, the relapse rate of the 5th year is up to 59%.Current treatment is mainly operation and Drug therapy, and operative treatment is mainly used in acute onset and Drug therapy when cannot solve, and it is larger to harm.Drug therapy is little to human body infringement, is the preferred option of cardiovascular and cerebrovascular disease, is mainly used in treating between conventional therapy, postoperative recuperation period at ordinary times.Chinese patent medicine because of its side effect little, can long-term taking, the advantages such as comprehensively regulating treating both the principal and secondary aspects of a disease as the drug of first choice for the treatment of cardiovascular and cerebrovascular disease, for meeting clinical needs, in conjunction with clinical application experience and experimental data, develop and a kind ofly treat the cardiovascular and cerebrovascular diseases caused Chinese medicine composition of obstruction of collaterals by blood stasis.
Summary of the invention
For meeting clinical needs, solve the defect that prior art exists, the present invention aims to provide cardiovascular and cerebrovascular diseases caused Chinese medicine composition of a kind for the treatment of obstruction of collaterals by blood stasis evident in efficacy, that have no side effect and preparation method thereof
To achieve these goals, technical scheme of the present invention is:
Treat the Chinese medicine composition that obstruction of collaterals by blood stasis is cardiovascular and cerebrovascular diseases caused, its composition comprises the raw material of following weight portion:
Rhizoma Dioscoreae Nipponicae 600-1800 part Rhizoma Chuanxiong 500-1500 part Moschus 0.05-1 part Borneolum Syntheticum 0.5-10 part.
Preferably, above-mentioned a kind ofly treat the cardiovascular and cerebrovascular diseases caused Chinese medicine composition of obstruction of collaterals by blood stasis, its composition comprises the raw material of following weight portion:
Rhizoma Dioscoreae Nipponicae 1200 parts, Rhizoma Chuanxiong 1000 parts, 0.2 part, Moschus, Borneolum Syntheticum 2.5 parts.
Preferably, the dosage form of described compositions is tablet, granule, capsule, drop pill, soft capsule.
The present invention also provides a kind of preparation method of above-mentioned composition, and following steps can be adopted to make:
(1) Moschus, Borneolum Syntheticum are pulverized, obtain mixed-powder, for subsequent use;
(2) get Rhizoma Dioscoreae Nipponicae in prescription, Rhizoma Chuanxiong, the 30-85% soak with ethanol adding 5-15 times of weight, after 30 minutes, is extracted 2-5 time, each 0.5-2.0 hour, filter, reclaim ethanol, be dried to dry cream, pulverize, add step (1) gained mixed-powder, mixing.Add conventional pharmaceutical adjuvants, conveniently technique is prepared into tablet, granule, capsule, drop pill, soft capsule.
The present invention also provides a kind of preparation method of above-mentioned composition, and following steps also can be adopted to make:
(1) Moschus, Borneolum Syntheticum are pulverized, obtain mixed-powder, for subsequent use;
(2) Rhizoma Dioscoreae Nipponicae in prescription, Rhizoma Chuanxiong is got, add the 30-85% soak with ethanol of 5-15 times of weight after 30 minutes, extract 2-5 time, each 0.5-2.0 hour, filter, reclaim ethanol, be concentrated into every ml concentrated solution and be equivalent to 1g crude drug, adopt macroporous resin to carry out post separation, loading parameter is: concentrated solution and weight resin volume ratio: 50-300ml: 100g, blade diameter length ratio: 1: 8, loading speed: 1-3 per hour times column volume; Elution parameters is: with the water of 3-8 times of column volume for eluting solvent, eluting is carried out with 1-3 per hour times column volume, discard the water liquid of eluting, then with the 30-85% ethanol of 3-8 times of column volume for eluting solvent, carry out eluting with 1-3 per hour times column volume, collect the ethanol of eluting, reclaim ethanol, be dried to dry cream, pulverize, add step (1) gained mixed-powder, mixing.Add conventional pharmaceutical adjuvants, conveniently technique is prepared into tablet, granule, capsule, drop pill, soft capsule.
Beneficial effect of the present invention is:
(1) theory of Chinese medical science and Chinese medicine modern study are combined, Be very effective.Rhizoma Chuanxiong, has blood circulation promoting and blood stasis dispelling, promoting of the circulation of QI and removing the obstruction in the collaterals, is monarch drug.Rhizoma Dioscoreae Nipponicae and Rhizoma Chuanxiong share, and playing effect of promoting flow of QI and blood, disperse blood stasis and dredge collateral altogether, is ministerial drug.Modern pharmacological research shows that in Rhizoma Chuanxiong, Rhizoma Dioscoreae Nipponicae, active substance is for improving blood flow, reducing the aspect effects such as blood fat obviously, but its effective ingredient is difficult to by blood brain barrier, and what do not reach medicine plays effective amount; Moschus, having has one's ideas straightened out logical closes, ward off the turbid effect of dirtyization, refreshment of can having one's ideas straightened out, promoting blood circulation to restore menstrual flow.For adjuvant drug; The pungent waking up the patient from unconsciousness by clearing away heat key of Borneolum Syntheticum, energy priming is up, and itself and Moschus share, and have assistant and make it merit, Fang Zhongwei makes medicine.Borneolum Syntheticum, Moschus priming are up, modern study its have and promote that other drug is by the effect of blood brain barrier, two kinds combine the cerebrovascular that is transported to of the effective substance maximum in Rhizoma Chuanxiong, Rhizoma Dioscoreae Nipponicae are played curative effect.Shown by pharmacology and clinical research: cardiovascular and cerebrovascular diseases caused for treatment obstruction of collaterals by blood stasis, particularly cerebrovascular disease is evident in efficacy.
(2) low, misery and the trouble that patient's Long-term taking medicine can be removed from of the cardiovascular and cerebrovascular diseases caused successful of Chinese medicine preparation of the present invention treatment obstruction of collaterals by blood stasis, short treating period, relapse rate;
(3) the present invention is Chinese patent medicine preparation, without chemical composition and additive, to human non-toxic's side effect, more meets natural, healthy consumption demand;
Additional aspect of the present invention and advantage will part provide in the following description, and part will become obvious from the following description, or be recognized by practice of the present invention.
Detailed description of the invention
Below in conjunction with instantiation, the present invention is described in detail.
Embodiment 1
A. the raw material of following weight portion is taken:
Rhizoma Dioscoreae Nipponicae 1200g, Rhizoma Chuanxiong 1000g, Moschus 0.2g, Borneolum Syntheticum 2.5g
B. following steps are adopted to prepare Chinese medicine composition:
(1) Moschus, Borneolum Syntheticum are pulverized, obtain mixed-powder, for subsequent use;
(2) get Rhizoma Dioscoreae Nipponicae in prescription, Rhizoma Chuanxiong, add 65% soak with ethanol of 10 times of weight after 30 minutes, extract 3 times, each 1 hour, filter, reclaim ethanol, be dried to dry cream, pulverize, add step (1) gained mixed-powder, mixing.Add appropriate dextrin, mixing, makes 1000 capsules, obtains a kind of capsule compositions of the present invention.
Embodiment 2
A. the raw material of following weight portion is taken:
Rhizoma Dioscoreae Nipponicae 800g, Rhizoma Chuanxiong 1050g, Moschus 0.15g, Borneolum Syntheticum 2.5g
B. following steps are adopted to prepare Chinese medicine composition:
(1) Moschus, Borneolum Syntheticum are pulverized, obtain mixed-powder, for subsequent use;
(2) get Rhizoma Dioscoreae Nipponicae in prescription, Rhizoma Chuanxiong, add 65% soak with ethanol of 10 times of weight after 30 minutes, extract 3 times, each 1 hour, filter, reclaim ethanol, be dried to dry cream, pulverize, add step (1) gained mixed-powder, mixing.Add appropriate dextrin, mixing, makes 1000 capsules, obtains a kind of capsule compositions of the present invention.
Embodiment 3
A. the raw material of following weight portion is taken:
Rhizoma Dioscoreae Nipponicae 1200g, Rhizoma Chuanxiong 1000g, Moschus 0.2g, Borneolum Syntheticum 2.5g
B. following steps are adopted to prepare Chinese medicine composition:
(1) Moschus, Borneolum Syntheticum are pulverized, obtain mixed-powder, for subsequent use;
(2) Rhizoma Dioscoreae Nipponicae in prescription, Rhizoma Chuanxiong is got, add 65% soak with ethanol of 10 times of weight after 30 minutes, extract 3 times, each 1 hour, filter, reclaim ethanol, be dried to dry cream, pulverize, add 100g dextrin, carboxymethyl starch sodium 36g, mixing, take ethanol as binding agent soft material, cross 20 mesh sieve granules, 60 DEG C of dryings, cross 20 mesh sieve granulate, add step (1) gained mixed-powder, carboxymethyl starch sodium 12g, magnesium stearate 2.5g, mixing, is pressed into 1500, obtains a kind of tablet composition of the present invention.
Embodiment 4
A. the raw material of following weight portion is taken:
Rhizoma Dioscoreae Nipponicae 1200g, Rhizoma Chuanxiong 1000g, Moschus 0.2g, Borneolum Syntheticum 2.5g
B. following steps are adopted to prepare Chinese medicine composition:
(1) Moschus, Borneolum Syntheticum are pulverized, obtain mixed-powder, for subsequent use;
(2) get Rhizoma Dioscoreae Nipponicae in prescription, Rhizoma Chuanxiong, add 65% soak with ethanol of 10 times of weight after 30 minutes, extract 3 times, each 1 hour, filter, reclaim ethanol, be dried to dry cream, pulverize, adding 500g dextrin, step (1) gained mixed-powder, mixing, take ethanol as binding agent soft material, crosses 20 mesh sieve granules, 60 DEG C of dryings, cross 20 mesh sieve granulate and namely obtain a kind of granule composite of the present invention.
Embodiment 5
A. the raw material of following weight portion is taken:
Rhizoma Dioscoreae Nipponicae 1200g, Rhizoma Chuanxiong 1000g, Moschus 0.2g, Borneolum Syntheticum 2.5g
B. following steps are adopted to prepare Chinese medicine composition:
(1) Moschus, Borneolum Syntheticum are pulverized, obtain mixed-powder, for subsequent use;
(2) Rhizoma Dioscoreae Nipponicae in prescription, Rhizoma Chuanxiong is got, add 65% soak with ethanol of 10 times of weight after 30 minutes, extract 3 times, each 1 hour, filter, reclaim ethanol, be concentrated into every ml concentrated solution and be equivalent to 1g crude drug, macroporous resin is adopted to carry out post separation, loading parameter: concentrated solution and weight resin volume ratio: 100ml: 200g, blade diameter length ratio: 1: 8, loading speed: 2 times of column volumes per hour; Elution parameters: with the water of 3 times of column volumes for eluting solvent, elution speed is that 2 times of column volumes per hour carry out eluting, discards the water liquid of eluting, again with the 30-85% ethanol of 5 times of column volumes for eluting solvent, elution speed is that 2 times of column volumes per hour carry out eluting, collects the ethanol of eluting, is dried to dry cream, pulverize, add step (1) gained mixed-powder, the obtained clear paste powder of mixing, adds the polyethylene glycol 6000 of 4 times of quality, put 90 DEG C of heating in water bath meltings, stir.Take methyl-silicone oil as condensing agent, temperature is 5 DEG C, drips apart from 3cm, dripping, drips fast 20d/min.Collect drop pill, the methyl-silicone oil on removing surface, dry, make drop pill.
Embodiment 5
A. the raw material of following weight portion is taken:
Rhizoma Dioscoreae Nipponicae 1200g, Rhizoma Chuanxiong 1000g, Moschus 0.2g, Borneolum Syntheticum 2.5g
B. following steps are adopted to prepare Chinese medicine composition:
(1) Moschus, Borneolum Syntheticum are pulverized, obtain mixed-powder, for subsequent use;
(2) Rhizoma Dioscoreae Nipponicae in prescription, Rhizoma Chuanxiong is got, add 65% soak with ethanol of 10 times of weight after 30 minutes, extract 3 times, each 1 hour, filter, reclaim ethanol, be concentrated into every ml concentrated solution and be equivalent to 1g crude drug, macroporous resin is adopted to carry out post separation, loading parameter: concentrated solution and weight resin volume ratio: 100ml: 200g, blade diameter length ratio: 1: 8, loading speed: 2 times of column volumes per hour, elution parameters: with the water of 3 times of column volumes for eluting solvent, elution speed is that 2 times of column volumes per hour carry out eluting, discard the water liquid of eluting, again with the 30-85% ethanol of 5 times of column volumes for eluting solvent, elution speed is that 2 times of column volumes per hour carry out eluting, collect the ethanol of eluting, be dried to dry cream, pulverize, add step (1) gained mixed-powder, the obtained clear paste powder of mixing, add the soybean oil of 1 times of weight, the Cera Flava heating of 1/10 times of weight is dissolved, mix homogeneously, cross colloid mill, be mixed into content, prepare glue traditionally, glue and content are loaded in capsule machine processed, temperature controls to carry out fill at 45 DEG C ~ 50 DEG C, with the soft capsule that 95% ethanol purge fill is good.
Embodiment 6
1) studies on acute toxicity
Choose 50 healthy rats, male and female half and half, body weight is 200 ± 10g, gavage in one day, the solution allocated with the Capsule content of embodiment 1, the adult being equivalent to 70Kg 100 times of daily measuring, Continuous Observation one week, rat has no adverse reaction, and health is good, and this product safety non-toxic is described.
2) pharmacology pharmacodynamic research
A. myocardial infarction and ischemia model research
Wistar rat 60, male and female half and half, are divided into 6 groups at random, often organize 10, are respectively dosage group and medicine low dose group in sham operated rats, myocardial infarction and ischemia model group, Propranolol group, medicine high dose group, medicine.Test medicine presses 10ml/kg gastric infusion, once a day, and continuous 8d.After 8d administration 1h, except sham operated rats, all the other respectively organize ligation arteria coronaria left anterior descending branch, form myocardial infarction and ischemia model.24h posterior external jugular vein injection azovan blue, 1ml/ only, cores after 1h dirty.Get heart sections, dye in 1% red tetrazolium liquid, through Pathologic image analysis system measurement, the percentage ratio of Zhan Zuo room, calculating myocardium infarcted region area.Result:
Table 1. is on the impact (x ± s) of rats with myocardial ischemia myocardial infarct size
Note: compare with sham operated rats, ###P < 0.001; Compare with model group, * * P < 0.01, * P < 0.05
Show: this product can reduce ischemic myocardium infarction size, alleviate cerebral edema, have certain protective effect to myocardial ischemia, can be used for the cardiovascular disease caused by obstruction of collaterals by blood stasis.
B. acute incomplete cerebral ischemic model research
Wistar rat 60, male and female half and half, are divided into 6 groups at random, often organize 10, are respectively dosage group and medicine low dose group in sham operated rats, cerebral ischemic model group, nimodipine group, medicine high dose group, medicine.Test medicine presses 10ml/kg gastric infusion, and once a day, Banded Rats bilateral common carotid arteries after 8d administration 1h, forms acute incomplete cerebral ischemic model.Sham operated rats not ligation common carotid artery, after operation 3h, broken end gets brain, and the dry weight in wet base method of a part surveys cerebral edema, measures SOD and MDA content in cerebral tissue after another part brain tissue homogenate.Result:
Table 2. is on the impact (x ± s) of rats with cerebral ischemia brain water content and cerebral tissue SOD, MDA
Note: compare with sham operated rats, #P < 0.05; Compare with model group, * P < 0.05
Show: this product can alleviate cerebral edema, have certain protective effect to cerebral ischemia, can be used for the cerebrovascular disease caused by obstruction of collaterals by blood stasis.
Although illustrate and describe embodiments of the invention, those having ordinary skill in the art will appreciate that: can carry out multiple change, amendment, replacement and modification to these embodiments when not departing from principle of the present invention and aim, scope of the present invention is by claim and equivalents thereof.
Claims (5)
1. treat the Chinese medicine composition that obstruction of collaterals by blood stasis is cardiovascular and cerebrovascular diseases caused, it is characterized in that, its composition comprises the raw material of following weight portion:
Rhizoma Dioscoreae Nipponicae 600-1800 part Rhizoma Chuanxiong 500-1500 part Moschus 0.05-1 part Borneolum Syntheticum 0.5-10 part.
2. according to claim 1ly a kind ofly treat the cardiovascular and cerebrovascular diseases caused Chinese medicine composition of obstruction of collaterals by blood stasis, it is characterized in that, its composition comprises the raw material of following weight portion:
Rhizoma Dioscoreae Nipponicae 1200 parts of Rhizoma Chuanxiongs 1000 parts of Moschus 0.2 part of Borneolum Syntheticum 2.5 parts.
3. according to claim 1 and 2ly a kind ofly treat the cardiovascular and cerebrovascular diseases caused Chinese medicine composition of obstruction of collaterals by blood stasis, it is characterized in that, the dosage form of described compositions is tablet, granule, capsule, drop pill, soft capsule.
4. a preparation method for compositions as claimed in claim 1 or 2, is characterized in that, adopts following steps to make:
(1) Moschus, Borneolum Syntheticum are pulverized, obtain mixed-powder, for subsequent use;
(2) Rhizoma Dioscoreae Nipponicae in prescription, Rhizoma Chuanxiong is got, add the 30-85% soak with ethanol of 5-15 times of weight after 30 minutes, reflux, extract, 2-5 time, each 0.5-2.0 hour, filter, reclaim ethanol, be dried to dry cream, pulverize, add step (1) gained mixed-powder, mixing, add conventional pharmaceutical adjuvants, conveniently technique is prepared into tablet, granule, capsule, drop pill, soft capsule.
5. a preparation method for compositions as claimed in claim 1 or 2, is characterized in that, following steps also can be adopted to make:
(1) Moschus, Borneolum Syntheticum are pulverized, obtain mixed-powder, for subsequent use;
(2) Rhizoma Dioscoreae Nipponicae in prescription, Rhizoma Chuanxiong is got, add the 30-85% soak with ethanol of 5-15 times of weight after 30 minutes, reflux, extract, 2-5 time, each 0.5-2.0 hour, filter, recycling design, is concentrated into every ml concentrated solution and is equivalent to 1g crude drug, macroporous resin is adopted to carry out post separation, loading parameter: concentrated solution and weight resin volume ratio: 100g: 80ml, blade diameter length ratio: 1: 8, loading speed: 1-3 per hour times column volume; Elution parameters: with the water of 3-8 times of column volume for eluting solvent, elution speed is that 1-3 per hour times column volume carries out eluting, discard the water liquid of eluting, then with the 30-85% ethanol of 3-8 times of column volume for eluting solvent, elution speed is that 1-3 per hour times column volume carries out eluting, collect the ethanol of eluting, reclaim ethanol, be dried to dry cream, pulverize, add step (1) gained mixed-powder, mixing.Add conventional pharmaceutical adjuvants, conveniently technique is prepared into tablet, granule, capsule, drop pill, soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510833658.5A CN105288049A (en) | 2015-11-26 | 2015-11-26 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases due to static blood obstructing the collaterals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510833658.5A CN105288049A (en) | 2015-11-26 | 2015-11-26 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases due to static blood obstructing the collaterals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105288049A true CN105288049A (en) | 2016-02-03 |
Family
ID=55186327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510833658.5A Pending CN105288049A (en) | 2015-11-26 | 2015-11-26 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases due to static blood obstructing the collaterals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105288049A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007124674A1 (en) * | 2006-04-20 | 2007-11-08 | Integrated Chinese Medicine Holdings, Ltd. | Compositions for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders |
| CN101766702A (en) * | 2006-03-27 | 2010-07-07 | 深圳市生物谷科技有限公司 | Medicinal combination containing borneol and musk |
-
2015
- 2015-11-26 CN CN201510833658.5A patent/CN105288049A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766702A (en) * | 2006-03-27 | 2010-07-07 | 深圳市生物谷科技有限公司 | Medicinal combination containing borneol and musk |
| WO2007124674A1 (en) * | 2006-04-20 | 2007-11-08 | Integrated Chinese Medicine Holdings, Ltd. | Compositions for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders |
Non-Patent Citations (5)
| Title |
|---|
| 孔令义: "《中药制药化学》", 30 April 2007, 中国医药科技出版社 * |
| 张金莲等: "《中医药学概论》", 31 December 2014, 清华大学出版社 * |
| 成都中医学院: "《中药学》", 31 December 1978, 上海科学技术出版社 * |
| 杨明: "《中药药剂学》", 31 August 2008, 上海科学技术出版社 * |
| 程艳静: "鼻脑通鼻用喷雾剂中活性成分及其配伍药代动力学研究", 《万方数据》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN104107299A (en) | Traditional Chinese medicine mixture for treating dysmenorrhoea | |
| CN104208302A (en) | Fructus rosae laevigatae healthy oral solution for reducing blood fat and preparation method thereof | |
| CN103083400A (en) | Drug for treating cardiovascular disease | |
| CN102973799B (en) | Pill used for post-anesthesia nerve injury | |
| CN104644901A (en) | Chinese medicinal preparation for long-term prevention and treatment of cardiovascular and cerebrovascular diseases at remission stage and preparation method of Chinese medicinal preparation | |
| CN102579610B (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN104740583A (en) | Traditional Chinese medicine preparation for relieving Crohn's disease and preparation method for traditional Chinese medicine preparation | |
| CN104645077A (en) | Traditional Chinese medicine preparation for preventing and treating ischemic cerebrovascular disease and preparation method of traditional Chinese medicine preparation | |
| CN101869671A (en) | Paste for waist, leg, shoulder and neck | |
| CN105250427A (en) | Pharmaceutical composition for treating heart diseases | |
| CN105012873A (en) | Health-care blood-fat-lowering evening primrose oral liquid and preparation method thereof | |
| CN102631415B (en) | Traditional Chinese medicine composite as well as product and application thereof | |
| CN106668782A (en) | External traditional Chinese medicine preparation for treating knee osteoarthritis and preparation method thereof | |
| CN105288049A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases due to static blood obstructing the collaterals | |
| CN102302655B (en) | Loquat acne removing capsules | |
| CN101983666A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method thereof | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN103989969A (en) | Traditional Chinese medicament for treating wind-cold obstruction type cervical spondylotic radiculopathy and preparation method thereof | |
| CN103784879A (en) | Compound traditional Chinese medicinal preparation for treating ischemic cerebrovascular diseases | |
| CN113577137B (en) | Traditional Chinese medicine composition for treating acne and preparation method and application thereof | |
| CN104189615B (en) | Traditional Chinese medicine preparation for treating metrorrhagia and metrostaxis, and preparation method of traditional Chinese medicine preparation | |
| CN104337909B (en) | A kind of Chinese medicine composition of the treatment gout containing Aspongopus | |
| CN102940656B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN113679781B (en) | Traditional Chinese medicine composition for treating tachyarrhythmia and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |
|
| WD01 | Invention patent application deemed withdrawn after publication |